# Dicot Pharma > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/dicotpharma). ## Overview Dicot Pharma is a Swedish clinical-stage pharmaceutical company focused on developing LIB-01, a novel treatment candidate for erectile dysfunction. The company’s work centers on drug discovery, clinical development, and intellectual property protection for a global sexual-health market. ## Products & services • LIB-01 erectile dysfunction drug candidate • Clinical development of oral formulations • Patent and IP portfolio management • Outlicensing and partnership-based commercialization - **Drug candidate development** (100%) — Development of LIB-01 through preclinical and clinical stages. - **Intellectual property** (0%) — Patent families, know-how, and related protection of the LIB-01 platform. - **Partnership commercialization** (0%) — Potential upfront, milestone, and royalty economics from licensing or partnering. - LIB-01 erectile dysfunction drug candidate - Clinical development of oral formulations - Patent and IP portfolio management - Outlicensing and partnership-based commercialization ## Customers Dicot Pharma does not yet sell a commercial product; its near-term counterparties are clinical trial sites, contract manufacturers, and research partners that support development of LIB-01. Longer term, the company’s commercial customers would be patients and prescribing physicians in the erectile dysfunction market, with value created through outlicensing or partnering with a pharmaceutical commercializer. - **Clinical research partners** (primary) — Trial sites, investigators, and CRO-type partners that execute phase studies for LIB-01. - **Manufacturing partners** (primary) — Specialized pharmaceutical manufacturers that produce study drug and placebo tablets. - **Pharmaceutical licensees** (primary) — Potential industrial partners that could outlicense development and commercialization rights. - **Future patients and prescribers** (secondary) — Men treated for erectile dysfunction and the physicians who prescribe the eventual product. - **Capital providers** (primary) — Equity investors and warrant holders financing the clinical development program. - Clinical trial sites that enroll patients and run studies - Contract manufacturers producing active substance and trial tablets - Potential pharma partners seeking licensing rights to LIB-01 - Future physicians and patients in erectile dysfunction treatment - Institutional investors funding development through equity or warrants ## Geography Dicot Pharma is headquartered in Sweden and develops LIB-01 for a global market. Its clinical work has involved multiple sites across three countries, while manufacturing and development partnerships are international in scope. - Headquartered in Sweden - Clinical study sites span three countries - Product target market is global, not country-specific - Manufacturing and partners are international - Commercial exposure will depend on future licensing territories ## Strategy Dicot Pharma’s strategy is to advance LIB-01 through clinical development and use data to support partnering or outlicensing. The company also seeks to broaden its pipeline over time, while protecting its intellectual property and preserving flexibility through external financing and industrial collaborations. - **Advance LIB-01 through clinical development** (short-term) — Clinical data are the main value driver for a precommercial biotech and determine partnering potential. - **Secure industrial and financial partnerships** (short-term) — Partnerships can fund development and convert clinical progress into non-dilutive economics. - **Protect intellectual property** (medium-term) — Patent and know-how protection are essential to preserve exclusivity and bargaining power. - **Broaden the product portfolio** (medium-term) — Additional indications or assets could reduce single-asset dependence and expand long-term value. - Advance LIB-01 from phase 2 toward later-stage development - Use clinical data to support industrial partnership discussions - Outlicense commercialization rights for upfront, milestone, and royalty value - Protect patent families and know-how around the LIB-01 platform - Evaluate expansion into additional indications and product opportunities ## Risks Dicot Pharma’s main risks are typical of a single-asset clinical biotech: clinical failure, funding needs, and dependence on key personnel. The company also faces intellectual property, manufacturing, and partnering risks because its value depends on protecting LIB-01 and converting development progress into a commercial agreement. - **Clinical development risk** [critical] — LIB-01 is still in development, so efficacy, safety, and trial design outcomes remain uncertain. - **Capital requirements** [high] — A precommercial biotech typically consumes cash before any product revenue is generated. - **Key personnel dependence** [high] — The business relies heavily on management, board members, and specialized scientific expertise. - **Intellectual property protection** [high] — Competitors may challenge patents or develop alternative compounds and know-how. - **Partnering and commercialization risk** [medium] — Future value depends on securing industrial partners on acceptable terms. - Clinical trials may fail to show sufficient efficacy or safety - Funding needs may exceed current expectations before commercialization - Key personnel departures could disrupt development and partnering - Patent or know-how protection may be challenged by competitors - Outlicensing terms may be delayed or less favorable than expected ## Accounting Dicot Pharma expenses development and project costs as incurred, so reported results are highly sensitive to the timing and scale of clinical activity. As a precommercial biotech, it also relies on judgment around share-based compensation, warrant exercises, and going-concern-style funding assumptions rather than revenue recognition complexity. - **Expensing of development costs** — No capitalized development asset or future amortization from current projects - **Clinical trial cost timing** — Comparability between quarters is limited - **Share-based compensation** — Affects operating expenses and equity - **Warrants and equity financing** — Dilution and financing capacity - Development costs are expensed as incurred, not capitalized - Clinical trial timing drives quarter-to-quarter cost volatility - No revenue recognition yet because the company is precommercial - Share-based compensation and warrants affect equity and expenses - Going-concern and funding assumptions are important for valuation --- *Last updated: 2026-08-11T04:04:51.762072+00:00*